Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Vitamin D and Breast Cancer Biomarkers in Female Patients
NCT01224678 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Vitamin D may help prevent breast cancer. PURPOSE: This randomized clinical trial is studying vitamin D and breast cancer biomarkers in female patients.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT vitamin D
Study Locations (20)
California
- Contra Costa Regional Medical Center — Martinez
- Camino Medical Group - Treatment Center — Mountain View
- El Camino Hospital Cancer Center — Mountain View
- Bay Area Breast Surgeons, Incorporated — Oakland
- CCOP - Bay Area Tumor Institute — Oakland
- Larry G Strieff MD Medical Corporation — Oakland
- Tom K Lee, Incorporated — Oakland
- Palo Alto Medical Foundation — Palo Alto
- — Pismo Beach
- Doctors Medical Center - San Pablo Campus — San Pablo
Florida
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital — Fort Lauderdale
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center — Jupiter
- CCOP - Mount Sinai Medical Center — Miami Beach
- Florida Hospital Cancer Institute at Florida Hospital Orlando — Orlando
Illinois
- Illinois CancerCare - Bloomington — Bloomington
- St. Joseph Medical Center — Bloomington
- Illinois CancerCare - Canton — Canton
- University of Chicago Cancer Research Center — Chicago
Alabama
- Regional Medical Center — Anniston
Connecticut
- Bendheim Cancer Center at Greenwich Hospital — Greenwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224678
The ClinicalTrials.gov registry entry for NCT01224678 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01224678 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01224678 about?
NCT01224678 is a clinical study titled "Vitamin D and Breast Cancer Biomarkers in Female Patients". RATIONALE: Vitamin D may help prevent breast cancer. PURPOSE: This randomized clinical trial is studying vitamin D and breast cancer biomarkers in female patients.
What is the current status of trial NCT01224678?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2010-10. Estimated completion is 2014-12.
What conditions does trial NCT01224678 study?
This clinical trial studies the following conditions: Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01224678?
The interventions under investigation include: placebo (OTHER), vitamin D (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01224678?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01224678 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.